이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Omeros 관리

관리 기준 확인 2/4

Omeros' CEO는 Greg Demopulos, Jun1994 에 임명되었습니다 의 임기는 30.08 년입니다. 총 연간 보상은 $ 7.69M, 11.9% 로 구성됩니다. 11.9% 급여 및 88.1% 보너스(회사 주식 및 옵션 포함). 는 $ 8.23M 가치에 해당하는 회사 주식의 3.5% 직접 소유합니다. 8.23M. 경영진과 이사회의 평균 재임 기간은 각각 8 년과 17.6 년입니다.

주요 정보

Greg Demopulos

최고 경영자

US$7.7m

총 보상

CEO 급여 비율	11.9%
CEO 임기	30.3yrs
CEO 소유권	3.5%
경영진 평균 재임 기간	4.8yrs
이사회 평균 재임 기간	17.8yrs

최근 관리 업데이트

Recent updates

Should Shareholders Reconsider Omeros Corporation's (NASDAQ:OMER) CEO Compensation Package?

Jun 05

Omeros posts preliminary results from COVID-19 patients treated with narsoplimab

May 28

CDC and CMS OKs Omeros' ICD-10 codes for HSCT-TMA diagnosis and narsoplimab

May 04

What Kind Of Shareholders Own Omeros Corporation (NASDAQ:OMER)?

Mar 03

CEO 보상 분석

Greg Demopulos 의 보수는 Omeros 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$200m
Mar 31 2024	n/a	n/a	-US$179m
Dec 31 2023	US$8m	US$917k	-US$175m
Sep 30 2023	n/a	n/a	-US$182m
Jun 30 2023	n/a	n/a	-US$185m
Mar 31 2023	n/a	n/a	-US$182m
Dec 31 2022	US$4m	US$882k	-US$182m
Sep 30 2022	n/a	n/a	-US$183m
Jun 30 2022	n/a	n/a	-US$173m
Mar 31 2022	n/a	n/a	-US$181m
Dec 31 2021	US$7m	US$848k	-US$192m
Sep 30 2021	n/a	n/a	-US$217m
Jun 30 2021	n/a	n/a	-US$211m
Mar 31 2021	n/a	n/a	-US$194m
Dec 31 2020	US$6m	US$817k	-US$173m
Sep 30 2020	n/a	n/a	-US$130m
Jun 30 2020	n/a	n/a	-US$108m
Mar 31 2020	n/a	n/a	-US$89m
Dec 31 2019	US$5m	US$794k	-US$147m
Sep 30 2019	n/a	n/a	-US$79m
Jun 30 2019	n/a	n/a	-US$102m
Mar 31 2019	n/a	n/a	-US$121m
Dec 31 2018	US$5m	US$770k	-US$127m
Sep 30 2018	n/a	n/a	-US$120m
Jun 30 2018	n/a	n/a	-US$88m
Mar 31 2018	n/a	n/a	-US$68m
Dec 31 2017	US$5m	US$748k	-US$53m

보상 대 시장: Greg 의 총 보상 ($USD 7.69M )은 US 시장( $USD 1.62M ).

보상과 수익: 회사가 수익성이 없는 동안 Greg 의 보상이 증가했습니다.

CEO

Greg Demopulos (65 yo)

30.3yrs

테뉴어

US$7,689,843

보상

Dr. Gregory A. Demopulos, M.D., also known as Greg, founded Omeros Corporation in June 1994 and has been its Chairman of the Board, Chief Executive Officer and President since June 1994. Dr. Demopulos serv...

리더십 팀

이름	위치	테뉴어	보상	소유권
Gregory Demopulos	Co-Founder	30.3yrs	US$7.69m	3.5% $ 7.4m
Peter Cancelmo	VP, General Counsel & Corporate Secretary	5.3yrs	US$852.63k	0.00035% $ 738.2
Pamela Palmer	Co-Founder	no data	데이터 없음	데이터 없음
David Borges	VP of Finance	less than a year	데이터 없음	0.052% $ 109.2k
George Gaitanaris	Chief Scientific Officer & VP of Science	12.7yrs	데이터 없음	데이터 없음
Peter Williams	Vice President of Human Resources	4.3yrs	데이터 없음	데이터 없음
Catherine Melfi	Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems	11.9yrs	데이터 없음	데이터 없음
Nadia Dac	VP & Chief Commercial Officer	3.7yrs	데이터 없음	데이터 없음
Andreas Grauer	VP & Chief Medical Officer	less than a year	데이터 없음	데이터 없음

4.8yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 관리: OMER 의 관리팀은 경험 ( 4.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Gregory Demopulos	Co-Founder	30.3yrs	US$7.69m	3.5% $ 7.4m
Thomas Cable	Lead Independent Director	29.7yrs	US$177.60k	0.061% $ 127.7k
Leroy Hood	Independent Director	23.5yrs	US$135.10k	0.13% $ 270.8k
Arnold Hanish	Independent Director	12yrs	US$137.60k	0.021% $ 45.1k
Peter Demopulos	Director	29.7yrs	US$122.60k	0.64% $ 1.4m
Thomas Bumol	Independent Director	5.6yrs	US$127.60k	0.017% $ 36.4k
Rajiv Shah	Independent Director	9.3yrs	US$140.10k	0% $ 0
Diana Perkinson	Independent Director	1.3yrs	US$174.66k	0% $ 0

17.8yrs

평균 재임 기간

70yo

평균 연령

경험이 풍부한 이사회: OMER 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 17.5 년).

Omeros 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Omeros Corporation Announces Executive Changes

Omeros Corporation, Annual General Meeting, Jun 06, 2024

Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer

Omeros Corporation, Annual General Meeting, Jun 23, 2023

Kurt Zumwalt Not to Stand for Re-Election as Class II Director of Omeros Corporation

Insufficient new directors

Recent updates

Omeros Corporation to Report Q2, 2024 Results on Aug 07, 2024

Omeros: Troubled Company Working Its Way Out Of The Morass

Omeros Corporation Announces Executive Changes

Omeros Corporation announced that it expects to receive $92.1 million in funding

Omeros Corporation to Report Q1, 2024 Results on May 15, 2024

Omeros Corporation, Annual General Meeting, Jun 06, 2024

Omeros Corporation (NasdaqGM:OMER) announces an Equity Buyback for $50 million worth of its shares.

Omeros Corporation to Report Q4, 2023 Results on Apr 01, 2024

Omeros: Still Worth A Look Despite Narsoplimab Woes

New major risk - Share price stability

New major risk - Negative shareholders equity

Omeros Corporation to Report Q3, 2023 Results on Nov 09, 2023

Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting

Price target decreased by 17% to US$5.83

Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer

Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy

New minor risk - Market cap size

Omeros Corporation to Report Q2, 2023 Results on Aug 09, 2023

Is Omeros (NASDAQ:OMER) A Risky Investment?

Omeros Corporation, Annual General Meeting, Jun 23, 2023

Kurt Zumwalt Not to Stand for Re-Election as Class II Director of Omeros Corporation

Omeros Corporation to Report Q1, 2023 Results on May 09, 2023

Omeros (NASDAQ:OMER) Is Making Moderate Use Of Debt

Price target increased by 17% to US$7.00

No longer forecast to breakeven

Consensus revenue estimates increase by 113%

Insufficient new directors

Omeros Corporation to Report Q3, 2022 Results on Nov 09, 2022

Omeros: Taking It To The Max

Omeros Corporation Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients in I-SPY COVID Trial

Omeros falls 11% after reporting clinical data for COVID-19 therapy

Omeros Corporation Receives Interim Response from FDA on Formal Dispute Resolution Request for Narsoplimab

Omeros: Managing An Investment After A Winning Trade

Omeros Corporation to Report Q2, 2022 Results on Aug 09, 2022

Omeros granted FDA’s Orphan Drug designation for PNH candidate

Omeros: Follow The Bouncing Ball

Price target increased to US$16.00

Omeros: On Death's Door

First quarter 2022 earnings released: US$0.63 loss per share (vs US$0.57 loss in 1Q 2021)

Omeros Corporation to Report Q1, 2022 Results on May 10, 2022

Consensus revenue estimates fall by 35%

No longer forecast to breakeven

Omeros Corporation, Annual General Meeting, Jun 17, 2022

Omeros: The Weight Of The Wait, A Conundrum

Insufficient new directors

Insufficient new directors

Consensus forecasts updated

Full year 2021 earnings: EPS misses analyst expectations

Insufficient new directors

Omeros Corporation to Report Q4, 2021 Results on Mar 01, 2022

Omeros: Despite Its Promise, The CRL Is A Huge Obstacle

Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMA

Price target decreased to US$15.00

Forecast to breakeven in 2024

Rayner Surgical Inc. completed the acquisition of OMIDRIA Franchise from Omeros Corporation (NasdaqGM:OMER).

Omeros: A New Year Beckons

Some Analysts Just Cut Their Omeros Corporation (NASDAQ:OMER) Estimates

Consensus revenue estimates increase to US$129.6m

Third quarter 2021 earnings released: US$0.36 loss per share (vs US$0.66 loss in 3Q 2020)

Third quarter 2021 earnings released: US$0.36 loss per share (vs US$0.66 loss in 3Q 2020)

Price target decreased to US$22.50

Omeros: What's Left

Price target decreased to US$25.29

Omeros: The Prize Is Nigh (Again)

Independent Director exercised options to buy US$156k worth of stock.

Second quarter 2021 earnings released: US$0.46 loss per share (vs US$0.61 loss in 2Q 2020)

Omeros: PDUFA Delay Presents An Opportunity

Co-Founder exercised options and sold US$801k worth of stock

Omeros Corporation Announces Narsoplimab Pivotal Trial Data in Oral Presentation at 2021 Annual Congress of the European Hematology Association